ICY­MI: FDA com­mis­sion­er calls for more on­shoring of clin­i­cal tri­als

FDA Com­mis­sion­er Robert Califf took to the stage twice in the last 12 hours in San Fran­cis­co, lin­ing up his pri­or­i­ties and dig­ging in on vac­cine mis­in­for­ma­tion, ac­cel­er­at­ed ap­proval re­forms, and a re­newed in­ter­est in on­shoring more clin­i­cal tri­als where com­pa­nies may be try­ing to save mon­ey, par­tic­u­lar­ly in on­col­o­gy.

Tak­ing the stage ear­ly Tues­day at the JP Mor­gan con­fer­ence, Califf told at­ten­dees that the re­cent­ly passed om­nibus spend­ing law is “re­al­ly im­por­tant” for the agency to more quick­ly help spon­sors ver­i­fy or dis­prove the ben­e­fits of ac­cel­er­at­ed ap­provals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER